The National Development and Reform Commission announced on the 30th that since May 1st, the maximum retail price limit for digestive drugs in 53 varieties has been reduced by an average of 17%. Among them, the average price of high-priced drugs has dropped by 22%, and it is expected to reduce the burden on consumers by more than 3 billion yuan each year.
The relevant person in charge of the Development and Reform Commission stated that it will intensify reforms, study the medicine price management system adapted to the new situation of the medical reform, and further improve the price formation mechanism. Including: strengthening the investigation and monitoring of costs and ex-factory price, laying the foundation for a reasonable determination of the ceiling price level; improving drug pricing methods, adopting drug economic evaluation for partial drug exploration and pricing by international price comparison methods, and conducting unified pricing for some drug exploration trials ; Further increase the price of high-priced drugs, especially to reduce the price of foreign investment in the development of drugs.
The Development and Reform Commission will also cooperate with the reform in the field of pharmaceutical production and circulation, focus on standardizing the price behavior of drug circulation, promote the integration and optimization of drug distribution companies, encourage the development of modern logistics industries, and establish a dynamic adjustment mechanism for drug prices, based on changes in drug production costs and market prices. Such factors as timely adjustment of drug prices.
The official pointed out that at present, China is fully implementing the new version of the GMP reform and national drug standards improvement action plan, all localities should fully consider the drug manufacturers to implement the new version of GMP transformation and upgrade the quality of the cost of the situation, in the adjustment of drug prices, properly grasp Price adjustment efforts. For a large number of generic drugs produced, reference should be made to the cost and market price adjustments of the advanced companies.
In recent years, the Development and Reform Commission has reduced the maximum retail price of many drugs by nearly 30 times. Last year, the Development and Reform Commission successively reduced the maximum retail prices of some hormones, endocrine and nervous system drugs, and antibiotics and circulatory system drugs used to treat infections and cardiovascular diseases, involving 244 species and more than 1,700 dosage forms. specification.
The relevant person in charge of the Development and Reform Commission stated that it will intensify reforms, study the medicine price management system adapted to the new situation of the medical reform, and further improve the price formation mechanism. Including: strengthening the investigation and monitoring of costs and ex-factory price, laying the foundation for a reasonable determination of the ceiling price level; improving drug pricing methods, adopting drug economic evaluation for partial drug exploration and pricing by international price comparison methods, and conducting unified pricing for some drug exploration trials ; Further increase the price of high-priced drugs, especially to reduce the price of foreign investment in the development of drugs.
The Development and Reform Commission will also cooperate with the reform in the field of pharmaceutical production and circulation, focus on standardizing the price behavior of drug circulation, promote the integration and optimization of drug distribution companies, encourage the development of modern logistics industries, and establish a dynamic adjustment mechanism for drug prices, based on changes in drug production costs and market prices. Such factors as timely adjustment of drug prices.
The official pointed out that at present, China is fully implementing the new version of the GMP reform and national drug standards improvement action plan, all localities should fully consider the drug manufacturers to implement the new version of GMP transformation and upgrade the quality of the cost of the situation, in the adjustment of drug prices, properly grasp Price adjustment efforts. For a large number of generic drugs produced, reference should be made to the cost and market price adjustments of the advanced companies.
In recent years, the Development and Reform Commission has reduced the maximum retail price of many drugs by nearly 30 times. Last year, the Development and Reform Commission successively reduced the maximum retail prices of some hormones, endocrine and nervous system drugs, and antibiotics and circulatory system drugs used to treat infections and cardiovascular diseases, involving 244 species and more than 1,700 dosage forms. specification.
You are always welcome to visit our company and taste our products. Contact: MS. Sunny Wang |
|
Product Description | |
Name | Canned Salmon |
Flavor | Brine, Oil, Salad, Chili |
Type | Shred, Flake, Chunk, Solid |
Certificates | EU, FDA, BRC, HALAL,HACCP,KOSHER |
Net weight | 140g, 160g, 170g, 185g, 200g, 1kg, 1.88k. |
Brand | Our brand or OEM, ODM |
Shelf life | 3/4 Years |
MOQ | 1X20'FCL |
Payment terms | T/T, L/C |
Delivery time | 25 days after label artwork confirmed and advance payment done. |
Packing | normal lid or easy open,paper label or lithio can, paper carton or shrinked by tray |
EU NO. | 3302/01034 |
RUSSIA NO. | 3302/01034 |
Shipping docs | Commercial Invoice |
Packing List | |
Bill of Lading | |
Certificate Of Origin/ Form A | |
Health Certificate | |
Veterinary Certificate | |
Catching certificate | |
Or as per customer`s request |
Salmon In Brine,Smoked Salmon Brine,Salmon Chunks In Brine,Sunflower Canned Salmon
Tropical Food Manufacturing (Ningbo) Co., Ltd. , https://www.tropical-food.com